Phase i trial of 7-hydroxystaurosporine and fludararbine phosphate: In vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 52, Issue 12, 2011, Pages 2284-2292

  Marti, Gerald E ^a   Stetler Stevenson, Maryalice ^a   Grant, Nicole Drbohlav ^a   White, Therese ^a   Figg, William D ^a   Tohnya, Tanyifor ^a   Jaffe, Elaine S ^a   Dunleavy, Kieron ^a   Janik, John E ^a   Steinberg, Seth M ^a   Wilson, Wyndham H ^a  

^a Division of Cell and Gene Therapies   (United States)

Author keywords

Cell death; CLL; Flow cytometry; Protein kinase inhibitor

Indexed keywords

7 HYDROXYSTAUROSPORINE; ALLOPURINOL; COTRIMOXAZOLE; FLUDARABINE PHOSPHATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER RELAPSE; CELL DEATH; CHRONIC LYMPHATIC LEUKEMIA; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; IN VIVO STUDY; INFECTION; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; RESERVOIR; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTOSIS; MALE; MIDDLE AGED; STAUROSPORINE; TREATMENT OUTCOME; VIDARABINE PHOSPHATE;

EID: 82255193028     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.589547     Document Type: Article

References (43)

1. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991;51:4888-4892.
2. Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Dif er 1995;6:927-936.
3. Kitada S, Zapata JM, Andreef M, Reed JC. Protein kinase inhibitors f avopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000;96: 393-397. (Pubitemid 30463354)
4. Tse AN, Carvajal R, Schwartz GK. Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 2007;13:1955-1960. (Pubitemid 46649860)
5. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002;21:1727-1738. (Pubitemid 34259036)
6. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92:376-387. (Pubitemid 30154819)
7. Senderowicz AM. Te cell cycle as a target for cancer therapy: basic and clinical f ndings with the small molecule inhibitors f avopiridol and UCN-01. Oncologist 2002;7(Suppl. 3):12-19.
8. Monks A, Harris ED, Vaigro-Wolf A, et al. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Invest New Drugs 2000;18:95-107. (Pubitemid 30261284)
9. Simon R, Freidlin B, Rubinstein L, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89: 1138-1147. (Pubitemid 27337928)
10. Bauer KS, Lush RM, Rudek MA, et al. A high-performance liquid chromatography method using ultraviolet and f uorescence detec tion for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr 2000;14:338-343. (Pubitemid 30642682)
11. Dive C, Gregory CD, Phipps DJ, et al. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multi-parameter flow cytometry. Biochim Biophys Acta 1992;1133: 275-285.
12. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001;19:2319-2333. (Pubitemid 32366984)
13. Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specif c high af nity binding to alpha1-acid glycoprotein in humans. Cancer Res 1999;59: 1054-1060. (Pubitemid 29135966)
14. Fuse E, Hashimoto A, Sato N, et al. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein. Pharm Res 2000;17:553-564. (Pubitemid 30416393)
15. Sampath D, Cortes J, Estrov Z, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006;107:2517-2524. (Pubitemid 43345576)
16. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin- containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633-3642.
17. Hiddemann W, Unterhalt M, Pott C, et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol 1993;20:28-31. (Pubitemid 23333775)
18. Hochster HS, Kim KM, Green MD, et al. Activity of f udarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol 1992;10: 28-32.
19. Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of f udarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790-794.
20. Puccio CA, Mittelman A, Lichtman SM, et al. A loading dose/continuous infusion schedule of f udarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 1991;9:1562-1569.
21. Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 1990;17:49-62. (Pubitemid 20356428)
22. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-1757.
23. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol Neoplasia 2008;13:471-483.
24. Dees EC, Baker SD, O'Reilly S, et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin Cancer Res 2005;11:664-671. (Pubitemid 40116893)
25. Hotte SJ, Oza A, Winquist EW, et al. Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II consortium study. Ann Oncol 2006;17:334-340. (Pubitemid 43160126)
26. Welch S, Hirte HW, Carey MS, et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007;106:305-310. (Pubitemid 47096653)
27. Kortmansky J, Shah MA, Kaubisch A, et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with f uorouracil in patients with advanced solid tumors. J Clin Oncol 2005;23:1875-1884. (Pubitemid 46211365)
28. Lara PN Jr, Mack PC, Synold T, et al. Te cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 2005;11:4444-4450. (Pubitemid 40825635)
29. Edelman MJ, Bauer KS Jr, Wu S, et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 2007;13:2667-2674. (Pubitemid 46788034)
30. Wang Q, Fan S, Eastman A, et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-965. (Pubitemid 26239383)
31. Sparreboom A, Chen H, Acharya MR, et al. effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine. Clin Cancer Res 2004;10:6840-6846. (Pubitemid 39383032)
32. Ramachandran A, Majumdar G. Acute tumour lysis syndrome after oral f udarabine in a patient with chronic lymphocytic leukaemia. Hematol J 2004;5:528-529. (Pubitemid 40045289)
33. Dizdar O, Yurekli BS, Purnak T, Aksu S, Haznedaroglu IC. Tumor lysis syndrome associated with f udarabine treatment in chronic lymphocytic leukemia. Ann Pharmacother 2004;38:1319-1320. (Pubitemid 38802187)
34. Hussain K, Mazza JJ, Clouse LH. Tumor lysis syndrome (TLS) following f udarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature. Am J Hematol 2003;72:212-215. (Pubitemid 36258614)
35. Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: an uncommon complication of f udarabine therapy of chronic lymphocytic leukemia. J Clin Oncol 1998;16:2313-2320. (Pubitemid 28309022)
36. Wang L, Abbasi F, Jasper GA, et al. Variables in the quantif cation of CD4 in normals and hairy cell leukemia patients. Cytometry B Clin Cytom 2011;80:51-56.
37. Jasper GA, Arun I, Venzon D, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom 2011;80:83-90.
38. Shaw RK, Boggs DR, Silberman HR, Frei E. A study of prednis one therapy in chronic lymphocytic leukemia. Blood 1961;17:182-189.
39. Flinn IW, Byrd JC, Furman RR, et al. Evidence of clinical activity in a phase 1 study of CAL-101, an oral P110d isoform-selective inhibitor of phosphatidylinositol 3-kinase, in patients with relapsed or refractory B-cell malignancies. Blood 2009;114(Suppl. 1): Abstract 922.
40. Herishanu Y, Perez-Galan P, Liu D, et al. Te lymph node micro-environment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-574.
41. Hoellenriegel J, Meadows SA, Wierda WG, et al. Phosphoinositide 3'-kinase (PI3K) delta inhibition with CAL-101 blocks B-cell receptor (BCR) signaling and the prosurvival actions of nurslike cells (NLC), in chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 48.
42. Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has signif cant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
43. Zent CS, LaPlant BR, Johnston PB, et al. Te treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010;116:2201-2207.